ClinicalTrials.Veeva

Menu

Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients

Myriad Genetic Laboratories logo

Myriad Genetic Laboratories

Status

Completed

Conditions

Prostate Cancer

Study type

Observational

Funder types

Industry

Identifiers

NCT01954004
PROCEDE-1000

Details and patient eligibility

About

This registry is intended to evaluate the impact of genomic test results towards selecting a first-line therapy option for newly diagnosed localized prostate cancer patients.

Enrollment

1,270 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Newly diagnosed (≤6 months), untreated patients with histologically proven adenocarcinoma of the prostate that have the following characteristics.
  • Clinically localized (no evidence on clinical or imaging studies of advanced disease).
  • No hormonal therapy including LHRH (luteinizing hormone-releasing hormone) agonist or antagonist, anti-androgen, estrogens or exogenous androgens, when applicable.
  • Sufficient amount of tissue remains from biopsy to perform genomic testing.

Exclusion criteria

  • Patients with a known history of hypogonadism

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems